Transcode Therapeutics, Inc. (RNAZ)

Number of records: 9
SEC FilingInsiderCompanyTrade DateTransactionSharesAvg. PriceTotal% HoldingsReturn
02-Oct-23 4:37 PM
View: 
Dudley Robert Michael
Chief Executive Officer
Director
Transcode Therapeutics, Inc. (RNAZ) 28-Sep-23Private Purchase 98,000$0.51$49,980.00119%
82.26K to 180.26K
02-Oct-23 4:39 PM
View: 
Fitzgerald Thomas A
Chief Financial Officer
Director
Transcode Therapeutics, Inc. (RNAZ) 28-Sep-23Private Purchase 49,350$0.51$25,168.50708%
6.97K to 56.32K
22-Jun-23 6:23 PM
View: 
Dudley Robert Michael
Chief Executive Officer
Director
Transcode Therapeutics, Inc. (RNAZ) 21-Jun-23Market Purchase 12,000$2.65$31,818.0017%
70.26K to 82.26K
(8%)
22-Jun-23 6:23 PM
View: 
Dudley Robert Michael
Chief Executive Officer
Director
Transcode Therapeutics, Inc. (RNAZ) 20-Jun-23Market Purchase 6,607$2.55$16,846.5010%
63.66K to 70.26K
(4%)
13-Jun-23 4:16 PM
View: 
Dudley Robert Michael
Chief Executive Officer
Director
Transcode Therapeutics, Inc. (RNAZ) 09-Jun-23Purchase 19,000$2.76$52,440.002%
893.11K to 912.11K
16-Sep-22 6:44 PM
View: 
Dudley Robert Michael
Chief Executive Officer
Director
10% Owner
Transcode Therapeutics, Inc. (RNAZ) 14-Sep-22Private Purchase 20,000$1.15$23,000.002%
873.11K to 893.11K
17-Jun-22 4:01 PM
View: 
Fitzgerald Thomas A
Chief Financial Officer
Director
Transcode Therapeutics, Inc. (RNAZ) 16-Jun-22Private Purchase 12,000$1.27$15,240.009%
127.38K to 139.38K
01-Jun-22 4:01 PM
View: 
Dudley Robert Michael
Chief Executive Officer
Director
10% Owner
Transcode Therapeutics, Inc. (RNAZ) 31-May-22Purchase 2,000$1.87$3,739.80< 1%
871.11K to 873.11K
01-Jun-22 4:01 PM
View: 
Dudley Robert Michael
Chief Executive Officer
Director
10% Owner
Transcode Therapeutics, Inc. (RNAZ) 27-May-22Private Purchase 28,000$1.84$51,643.203%
843.11K to 871.11K